Lantheus Holdings, Inc. (LNTH)
$
75.56
+0.04 (0.05%)
Key metrics
Financial statements
Free cash flow per share
6.8876
Market cap
5.2 Billion
Price to sales ratio
3.3825
Debt to equity
0.5277
Current ratio
5.7410
Income quality
2.0646
Average inventory
68.6 Million
ROE
0.2282
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. The operating expenses amount to $531,312,000.00 encompassing various operational costs incurred. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; and numerous other agents, including Xenon-133 for assessing pulmonary function and Neurolite for identifying brain blood flow issues post-stroke. The gross profit stands at $988,291,000.00 highlighting the company's profitability from core operations. Additionally, Cardiolite, Thallium-201, and Gallium-67 are among the agents used to detect cardiovascular diseases, infections, and cancerous tumors. The total costs and expenses for the company are $1,085,346,000.00 reflecting its overall spending. In the realm of therapeutics, the company also offers AZEDRA for treating patients, and various other products aimed at diagnosing and treating prostate cancer, such as PYLARIFY. The weighted average number of shares outstanding is 69,199,000.00 highlighting the company's shareholder base. Lantheus Holdings also develops innovative products like flurpiridaz F 18 and an investigational monoclonal antibody, leronlimab. The net income ratio is 0.20 reflecting the company's profitability margin as it serves radio pharmacies, distributors, and healthcare providers globally. As for its market positioning, the stock is reasonably priced at $75.52 appealing to a broad range of investors. With a mid-range market capitalization of $5,227,679,048.00 the company is a steady performer in the healthcare sector. The stock has an average trading volume of 1,063,642.00 indicating moderate liquidity. It is a key player in the diagnostic and therapeutic products industry, contributing significantly to the overall market landscape, and it belongs to the healthcare sector, driving innovation and growth in various medical fields. Strategic partnerships with industry leaders further enhance its market presence and support the development of cutting-edge solutions in the healthcare arena.
Is Lantheus Holdings, Inc. (LNTH) a good investment?
Investing in Lantheus Holdings, Inc. (LNTH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Lantheus Holdings, Inc. (LNTH)'s stock forecast?
Analysts predict Lantheus Holdings, Inc. stock to fluctuate between $73.11 (low) and $126.89 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lantheus Holdings, Inc.'s market capitalization?
As of 2025-05-30, Lantheus Holdings, Inc.'s market cap is $5,227,679,048, based on 69,185,800 outstanding shares.
How does Lantheus Holdings, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Lantheus Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Lantheus Holdings, Inc. (LNTH) stock?
To buy Lantheus Holdings, Inc. (LNTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LNTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Lantheus Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Lantheus Holdings, Inc. perform in the last earnings report?
Revenue: $1,533,910,000 | EPS: $4.52 | Growth: -5.64%.
Where can I find Lantheus Holdings, Inc.'s investor relations reports?
Visit https://www.lantheus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lantheus Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Lantheus Holdings, Inc. stock?
All-time high: $126.89 (2024-07-16) | All-time low: $15.95 (2021-01-29).
What are the key trends affecting Lantheus Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
seekingalpha.com
Lantheus shares fell 25% post-Q1 2025 report due to disappointing EPS guidance and not meet analysts' expectations. EPS reduction was driven by flat PYLARIFY sales and changes in Medicare coverage, impacting profitability and gross margins. Strategic transformation includes divesting the low-margin SPECT segment and acquiring LMI and Evergreen to expand into lucrative Alzheimer's and cancer diagnostics markets.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025.
See all news
